OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
VIR
Vir Biotechnology, Inc.
There isn't enough reported data to score VIR yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
VIR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Under pressure | |
| Strong |
VIR's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
VIR PE Valuation
VIR has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
VIR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect VIR's losses to grow, with revenue declining. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
VIR Earnings Per Share
VIR and OSCR do not have enough comparable growth data to identify a winner.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over VIR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
VIR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $238.9M | +19583% |
| Q4 2025 | $64.1M | +418% |
| Q3 2025 | $240K | -90% |
| Q2 2025 | $1.2M | -61% |
| Q1 2025 | $3M | -95% |
| Q4 2024 | $12.4M | -26% |
| Q3 2024 | $2.4M | -9.8% |
| Q2 2024 | $3.1M | -19% |
VIR's revenue is recovering but still below its 2022 peak: $239M last quarter, up 19583% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 31% | +9785 points |
| Q4 2025 | -75% | +872 points |
| Q3 2025 | -72268% | -62549 points |
| Q2 2025 | -9754% | -4596 points |
| Q1 2025 | -4602% | -4460 points |
| Q4 2024 | -947% | -119 points |
| Q3 2024 | -9719% | -2643 points |
| Q2 2024 | -5159% | +509 points |
VIR has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over VIR on cash generation, producing positive trailing cash flow while its opponent burns cash.
VIR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $123.3M | +$246.1M |
| Q1 2026 | -$132.8M | -$53M |
| Q4 2025 | -$26.2M | +$63.8M |
| Q3 2025 | -$167.9M | +$5.9M |
| Q2 2025 | -$122.8M | -$44.2M |
| Q1 2025 | -$79.7M | +$31.5M |
| Q4 2024 | -$90M | +$19.4M |
| Q3 2024 | -$173.8M | -$14.3M |
VIR has burned cash in most quarters: −$204M over the past year, against −$466M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
VIR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +15% | +21.5M shares |
| 1 year | +22% | +30.4M shares |
| 3 years | +26% | +34.8M shares |
| 5 years | +26% | +35.1M shares |
| Available history | +56% | +60.5M shares |
VIR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q2 2022 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
VIR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -1.0x | Net Cash |
| Q3 2022 | -0.6x | Net Cash |
| Q2 2022 | -1.1x | Net Cash |
| Q1 2022 | -0.5x | Net Cash |
| Q4 2021 | -0.8x | Net Cash |
VIR has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
VIR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.2 | Neutral |
| Stochastic | 76.5 | Neutral |
VIR's weekly RSI is 63 (neutral) and its Stochastic is 76 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
VIR PE vs Healthcare Sector
| Metric | VIR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
VIR has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
VIR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.2 | 8.1% above |
| 20 week MA | $10.4 | 17% above |
| 50 week MA | $9.12 | 33% above |
| 100 week MA | $7.75 | 56% above |
| 200 week MA | $10.7 | 13% above |
VIR has climbed back above all five of its weekly moving averages, and it's now 13% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over VIR on returns for 2026, with the stronger performance.
VIR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.4 | $29.5 | +139% |
| 2021 | $29.5 | $41.8 | +41% |
| 2022 | $41.8 | $25.7 | -38% |
| 2023 | $25.7 | $10.1 | -61% |
| 2024 | $10.1 | $7.47 | -26% |
| 2025 | $7.47 | $6.00 | -20% |
| 2026 YTD | $6.00 | $12.1 | +102% |
VIR has finished four years in a row lower, and it's up 102% so far in 2026.